{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:21:39Z","timestamp":1791044499839,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI-118389"],"award-info":[{"award-number":["AI-118389"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.vaccine.2017.12.064","type":"journal-article","created":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T11:02:19Z","timestamp":1515063739000},"page":"827-832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Enhancing toxin-based vaccines against botulism"],"prefix":"10.1016","volume":"36","author":[{"given":"Amanda","family":"Przedpelski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Tepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Zuverink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Pellet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph T.","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.12.064_b0005","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/mr.46.1.86-94.1982","article-title":"Bacterial toxins: a table of lethal amounts","volume":"46","author":"Gill","year":"1982","journal-title":"Microbiol Rev"},{"key":"10.1016\/j.vaccine.2017.12.064_b0010","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1128\/JB.01180-06","article-title":"Genetic diversity among Botulinum Neurotoxin-producing clostridial strains","volume":"189","author":"Hill","year":"2007","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2017.12.064_b0015","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1152\/physrev.2000.80.2.717","article-title":"Neurotoxins affecting neuroexocytosis","volume":"80","author":"Schiavo","year":"2000","journal-title":"Physiol Rev"},{"key":"10.1016\/j.vaccine.2017.12.064_b0020","unstructured":"Notice of CDC's discontinuation of investigational pentavalent (ABCDE) botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins. MMWR Morbidity and mortality weekly report; 2011;60:1454\u20135."},{"key":"10.1016\/j.vaccine.2017.12.064_b0025","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fimmu.2015.00170","article-title":"Intranasal vaccination with an engineered influenza virus expressing the receptor binding subdomain of botulinum neurotoxin provides protective immunity against botulism and influenza","volume":"6","author":"Li","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2017.12.064_b0030","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.4161\/hv.28937","article-title":"Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based Semliki Forest virus replicon vectors","volume":"10","author":"Yu","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.12.064_b0035","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2172-11-36","article-title":"Adenovirus F protein as a delivery vehicle for botulinum B","volume":"11","author":"Clapp","year":"2010","journal-title":"BMC Immunol"},{"key":"10.1016\/j.vaccine.2017.12.064_b0040","first-page":"367","article-title":"An adenoviral vector-based mucosal vaccine is effective in protection against botulism","volume":"16","author":"Xu","year":"2009","journal-title":"GeneTher"},{"key":"10.1016\/j.vaccine.2017.12.064_b0045","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1016\/j.vaccine.2011.04.045","article-title":"Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge","volume":"29","author":"Mustafa","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.12.064_b0050","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.4049\/jimmunol.174.4.2190","article-title":"A novel neurotoxoid vaccine prevents mucosal botulism","volume":"174","author":"Kobayashi","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.12.064_b0055","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/S0264-410X(02)00157-3","article-title":"Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid","volume":"20","author":"Torii","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.12.064_b0060","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/0041-0101(95)00072-T","article-title":"Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen","volume":"33","author":"LaPenotiere","year":"1995","journal-title":"Toxicon: Off J Int Soc Toxinol"},{"key":"10.1016\/j.vaccine.2017.12.064_b0065","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0300-9084(00)01173-1","article-title":"Development of vaccines for prevention of botulism","volume":"82","author":"Byrne","year":"2000","journal-title":"Biochimie"},{"key":"10.1016\/j.vaccine.2017.12.064_b0070","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1586\/erv.13.37","article-title":"What next for botulism vaccine development?","volume":"12","author":"Webb","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.12.064_b0075","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1128\/IAI.01025-07","article-title":"Subunit vaccine against the seven serotypes of botulism","volume":"76","author":"Baldwin","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.12.064_b0080","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1128\/IAI.00382-13","article-title":"Enhancing the protective immune response against botulism","volume":"81","author":"Przedpelski","year":"2013","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.12.064_b0085","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1016\/j.vaccine.2009.05.030","article-title":"Production of catalytically inactive BoNT\/A1 holoprotein and comparison with BoNT\/A1 subunit vaccines against toxin subtypes A1, A2, and A3","volume":"27","author":"Webb","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.12.064_b0090","first-page":"9","article-title":"Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism","author":"Webb","year":"2017","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.vaccine.2017.12.064_b0095","unstructured":"Henderson I, Shearer J, Swiderski W, Metcalfe M, Clagett K, Niemuth N, et al. Protection against botulinum neurotoxin exposure in guinea pigs passively immunized with immune globulin purified from human volunteers vaccinated with recombinant botulinum vaccine (rBVA\/B). In: Ninth annual conference on vaccine research, Baltimore, MD S19; 2006."},{"key":"10.1016\/j.vaccine.2017.12.064_b0100","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1128\/IAI.01252-08","article-title":"Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes","volume":"77","author":"Shone","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.12.064_b0105","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1128\/IAI.00843-07","article-title":"Recombinant holotoxoid vaccine against botulism","volume":"76","author":"Pier","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.12.064_b0110","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s11095-015-1816-x","article-title":"In vivo toxicity and immunological characterization of detoxified recombinant botulinum neurotoxin type A","volume":"33","author":"Ravichandran","year":"2016","journal-title":"Pharm Res"},{"key":"10.1016\/j.vaccine.2017.12.064_b0115","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1126\/science.1214270","article-title":"Botulinum neurotoxin is shielded by NTNHA in an interlocked complex","volume":"335","author":"Gu","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.12.064_b0120","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1365-2958.2003.03872.x","article-title":"The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction","volume":"51","author":"Rummel","year":"2004","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.vaccine.2017.12.064_b0125","first-page":"27","article-title":"Purification of Clostridium botulinum type A neurotoxin","volume":"145","author":"Malizio","year":"2000","journal-title":"Methods Mol Biol (Clifton, NJ)"},{"key":"10.1016\/j.vaccine.2017.12.064_b0130","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1128\/AEM.07967-11","article-title":"Purification and characterization of a novel subtype a3 botulinum neurotoxin","volume":"78","author":"Tepp","year":"2012","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.vaccine.2017.12.064_b0135","doi-asserted-by":"crossref","DOI":"10.1128\/AEM.00201-11","article-title":"Purification, modeling and analysis of neurotoxin BoNT\/A5 from Clostridium botulinum Strain A661222","author":"Jacobson","year":"2011","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.vaccine.2017.12.064_b0140","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1128\/AEM.01882-09","article-title":"Expression of the Clostridium botulinum A2 neurotoxin gene cluster proteins and characterization of the A2 complex","volume":"76","author":"Lin","year":"2010","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.vaccine.2017.12.064_b0145","first-page":"1","article-title":"Purification and characterization of botulinum neurotoxin FA from a genetically modified Clostridium botulinum strain","author":"Pellett","year":"2016","journal-title":"mSphere"},{"key":"10.1016\/j.vaccine.2017.12.064_b0150","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1128\/IAI.00536-13","article-title":"Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, neuronal cell cultures, and in vitro","volume":"81","author":"Whitemarsh","year":"2013","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.12.064_b0155","first-page":"96","article-title":"Standardized assay for Clostridium botulinum toxins","volume":"61","author":"Schantz","year":"1978","journal-title":"J Assoc Off Anal Chem"},{"key":"10.1016\/j.vaccine.2017.12.064_b0160","series-title":"Laboratory diagnosis of infectious diseases: principles and practice","first-page":"111","article-title":"Botulism","author":"Hatheway","year":"1988"},{"key":"10.1016\/j.vaccine.2017.12.064_b0165","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/toxsci\/kfr354","article-title":"Novel application of human neurons derived from induced pluripotent stem cells for highly sensitive botulinum neurotoxin detection","volume":"126","author":"Whitemarsh","year":"2012","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.vaccine.2017.12.064_b0170","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.vascn.2010.01.003","article-title":"Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination","volume":"61","author":"Pellett","year":"2010","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.vaccine.2017.12.064_b0175","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1016\/j.febslet.2007.08.078","article-title":"A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies","volume":"581","author":"Pellett","year":"2007","journal-title":"FEBS Lett"},{"key":"10.1016\/j.vaccine.2017.12.064_b0180","doi-asserted-by":"crossref","first-page":"7672","DOI":"10.4049\/jimmunol.0902874","article-title":"Tracking the total CD8 T cell response to infection reveals substantial discordance in magnitude and kinetics between inbred and outbred hosts","volume":"183","author":"Rai","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2017.12.064_b0185","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.1073\/pnas.89.13.6207","article-title":"Reversion of recombinant toxoids: mutations in diphtheria toxin that partially compensate for active-site deletions","volume":"89","author":"Killeen","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2017.12.064_b0190","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1432-1033.1994.tb19926.x","article-title":"Antagonism of the intracellular action of botulinum neurotoxin type A with monoclonal antibodies that map to light-chain epitopes","volume":"219","author":"Cenci Di Bello","year":"1994","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.vaccine.2017.12.064_b0195","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1128\/IAI.00405-09","article-title":"Antibody protection against botulinum neurotoxin intoxication in mice","volume":"77","author":"Cheng","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.12.064_b0200","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/protein\/gzq111","article-title":"Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin","volume":"24","author":"Garcia-Rodriguez","year":"2011","journal-title":"Protein Eng Des Sel"},{"key":"10.1016\/j.vaccine.2017.12.064_b0205","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1128\/IAI.00063-15","article-title":"The C-terminal heavy-chain domain of botulinum neurotoxin a is not the only site that binds neurons, as the N-terminal heavy-chain domain also plays a very active role in toxin-cell binding and interactions","volume":"83","author":"Ayyar","year":"2015","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.12.064_b0210","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1128\/iai.63.7.2738-2742.1995","article-title":"Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli","volume":"63","author":"Clayton","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2017.12.064_b0215","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.molimm.2006.03.011","article-title":"Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT\/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT\/A","volume":"44","author":"Dolimbek","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1016\/j.vaccine.2017.12.064_b0220","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.imbio.2010.12.009","article-title":"Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies","volume":"216","author":"Atassi","year":"2011","journal-title":"Immunobiology"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17318261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17318261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:23:20Z","timestamp":1759400600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17318261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0264410X17318261"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.12.064","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing toxin-based vaccines against botulism","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.12.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}